Teva Pharmaceutical Industries Limited Announces Phase IV Unite Study Shows Ajovy® (Fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

Teva Pharmaceutical Industries Limited announced that data from the UNITE study presented at the World Congress of Neurology in Montreal, Canada, show that AJOVY® reduced migraine attacks and...

Related Keywords

Canada ,Montreal ,Quebec ,Verena Ramirez Campos ,Teva Pharmaceutical Industries ,Teva Pharmaceuticals ,World Congress ,Patient Health ,Teva Pharmaceutical Industries Limited ,Global Senior Medical Director ,Monthly Migraine Days ,Hamilton Rating Scale ,Headache Impact Test ,Clinical Global Impression Severity ,Markets ,